Stay updated on Nivolumab in Resectable Osteosarcoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Resectable Osteosarcoma Clinical Trial page.

Latest updates to the Nivolumab in Resectable Osteosarcoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision tag was updated from v3.5.2 to v3.5.3, reflecting a newer version of the ClinicalTrials.gov record.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision label updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. No other visible changes to study details.SummaryDifference0.0%

- Check90 days agoChange DetectedAdministrative updates were made: a new revision (v3.4.2) and several date stamps were added. Older notices and some institutional references were removed, with no changes to the study data or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check97 days agoChange DetectedAdded a government funding lapse notice and updated the page revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.4%

Stay in the know with updates to Nivolumab in Resectable Osteosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Resectable Osteosarcoma Clinical Trial page.